drugset
drugset / Trial / NCT04877080

CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL

NCT04877080 ↗

Phase 1 Withdrawn 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm, open-label, single-center prospective study to determine the safety and efficacy of Fast Dual CAR-T cells in patients diagnosed with CD19+ refractory/relapsed B cell non-Hodgkinlymphoma (R/R B-NHL).

Timeline

Start
2021-05-05
Primary completion
2023-06-30
Completion
2023-12-31

Outcome

Outcome not reported

Stopped: “The PI decides to withdraw the research.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Fast Dual CAR-T Injection Cell therapy 100000 cells/kg Intravenous
Subject Fast Dual CAR-T Injection Cell therapy 500000 cells/kg Intravenous

Indications

B-cell non-Hodgkin lymphoma